Employment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis
Open Access
- 25 April 2019
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 19 (1) , 82
Abstract
There is a paucity of data on long term clinical effects of high frequency chest wall oscillation (HFCWO) in the Bronchiectasis population. Other therapies such as nebulized mucolytics and long term antibiotics have proven benefit on quality of life and exacerbation rate. In this study a treatment algorithm that included HFCWO as a component was initiated to see what the long term effects of the proposed algorithm were on lung function, antibiotic use, and exacerbation rates. This was an observational comparative retrospective cohort study from database of patients with Bronchiectasis. Patients with > 2 exacerbations and significant symptom burden were enrolled to receive a treatment algorithm. The algorithm included: nebulized bronchodilators, mucolytics (hypertonic saline (3–7%) or n-acetylcysteine) inhaled daily or twice daily, thrice weekly macrolide therapy when appropriate, and high frequency chest wall oscillation (HFCWO) therapy (daily to twice daily per issued protocol) Outcomes from the cohort were analyzed for the subsequent twelve months after initiation to observe longitudinal lung function and clinical outcomes. Chart review was then done to obtain data the year prior to the start of the algorithm in this same cohort of patients. Sixty-five patients received the Smart Vest® HFCWO system and were enrolled into the algorithm for treatment during the study period. Of the sixty-five patients, forty-three were eligible due to adequate 1-year baseline and follow up data at the time of the study initiation. The mean FEV1 remained stable at 1-year post enrollment (1.85 ± 0.60 L pre vs 1.89 ± 0.60 L post, p = NS) and the number of exacerbations requiring hospitalization was reduced (1.3 ± 1.0 pre vs. 0.46 ± 0.81 hospitalizations, post initiation, p < 0.0001). Antibiotic use overall was also reduced (2.5 ± 0.86 courses/year pre vs 2.1 ± 0.92 courses per year post initiation, p < 0.0001). Standardized care for Bronchiectasis involving an algorithm for Mucociliary clearance that centers on initiation of HFCWO may help to reduce lung function decline, need for oral antibiotics, and reduced hospitalization rate.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (5KL2TR001419-02)
- Cystic Fibrosis Foundation (Solomon18YO)
This publication has 31 references indexed in Scilit:
- Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasisBMC Pulmonary Medicine, 2013
- Cystic Fibrosis Pulmonary GuidelinesAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis BronchiectasisJAMA, 2013
- Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosisThorax, 2013
- The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasisRespiratory Medicine, 2012
- Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasisRespiratory Medicine, 2011
- British Thoracic Society guideline for non-CF bronchiectasisThorax, 2010
- A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis*Chest, 2005
- Treatment of Idiopathic Bronchiectasis With Aerosolized Recombinant Human DNase IChest, 1998
- Short-Term Recombinant Human DNase in Bronchiectasis. Effect on Clinical State and In Vitro Sputum TransportabilityAmerican Journal of Respiratory and Critical Care Medicine, 1996